GB
Genome Biologics
Genome Biologics develops tissue-specific RNA interference (RNAi) therapies that target the transcriptome associated with cardiovascular and cardiometabolic diseases. This approach aims to reduce disease progression by precisely silencing disease-related genes, offering a potential therapeutic solution for patients with these conditions.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$11.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Genome Biologics develops tissue-specific RNA interference (RNAi) therapies that target the transcriptome associated with cardiovascular and cardiometabolic diseases. This approach aims to reduce disease progression by precisely silencing disease-related genes, offering a potential therapeutic solution for patients with these conditions.